PharmaLectures.com

Courses › Pharma training by line of business › Pricing and contracts in Europe for the biologics and biosimilars maker: numbers and clauses

Pricing and contracts in Europe for the biologics and biosimilars maker: numbers and clauses

Your team signs European pricing contracts that survive the first authority review.

  • 6 audio modulesthree lengths each
  • 1 h to 5 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Biologics and biosimilarswho it is written for

Why this training matters

The French Economic Committee for Health Products turns down your price. Your team digs for the contract terms and finds a rebate clause two people read two ways. Entry for the new indication stalls for months while everyone argues over one sentence.

What changes after this course

Your team drafts rebate and price clauses that hold up under national authority review, and files dossiers that answer the first question asked. You hold a certificate per learner and a training record per person, each backed by a recorded questionnaire.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your market access team stops guessing what the German Federal Joint Committee wants in an early benefit assessment under the Pharmaceutical Market Restructuring Act. They file a dossier built to the Federal Joint Committee's dossier requirements, so the review does not come back with round after round of requests for more clinical data.

Contract negotiators spot a most favored nation clause before it is signed. They write rebate and price adjustment wording that holds across borders, even when the French Economic Committee for Health Products demands a mandatory rebate. Your legal counsel signs off in days, because the draft already answers the questions they would have sent back.

When a competing biosimilar reaches the market, product managers know what to do on day one. They price in tiers that parallel trade cannot easily undercut, and they decide at once whether a volume-based agreement or an outcomes-based contract fits the tender in front of them.

At a post-launch reimbursement re-evaluation, the real-world evidence and compliance data are already collected and filed. Authorities get straight answers. Your company avoids a price clawback caused by a badly documented rebate term or an incomplete biosimilar tender submission.

Who needs this training

  • Market Access Manager for Europe

    The German Federal Joint Committee finds no added benefit for a new biologic, and you must decide between a price negotiation and a new evidence submission.

  • Commercial Director for Biosimilars

    A regional tender asks for a steep discount, and you need to know what that price does to external reference pricing in neighboring countries before you bid.

  • European Legal Counsel

    Sales sends a draft agreement with a vague rebate clause, and you must spot the dispute and clawback risk before anyone signs.

  • Biologic Product Launch Lead

    The pricing proposal stalls because the real-world evidence does not match what the National Institute for Health and Care Excellence asks for in the United Kingdom.

Roles: Owner, CEO and board, Business development and export sales, Finance, pricing and tenders

Businesses: Biologics and biosimilars

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Write a value assessment dossier that meets the national health technology assessment requirements for your biologic.
  2. Structure a dossier for the German early benefit assessment so it answers the Federal Joint Committee's questions the first time.
  3. Draft contract clauses that stop one country's price from automatically lowering the price in another.
  4. Identify the rebate triggers hidden in a standard European supply agreement before anyone signs it.
  5. Calculate how a competing biosimilar entering the market changes the price position of your originator biologic.
  6. Produce the real-world evidence file that a post-launch reimbursement re-evaluation asks for.

What the company gets

  • Your market access submissions reach national health authorities complete, so reviews stop stalling on requests for missing documents.
  • Your legal team stops spending weeks rewriting ambiguous rebate clauses in European supply contracts.
  • Your company avoids sudden revenue drops caused by external reference pricing that nobody tracked.
  • Authorities receive straight answers and complete data files during post-launch rebate reconciliations.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 6 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 30 min25 min a module, for regulatory, quality and business-development staff
Expanded5 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing1 h
Finance, pricing and tendersBriefing1 h
Owner, CEO and boardBriefing1 h

Course outline: 6 modules

6 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Map the European pricing systems and spot every external reference trigger

    • Why one low price in a small country drags down your price in larger ones.
    • How to read which countries reference which, before you agree any national price.
    • The launch order that keeps your lowest price from becoming the number everyone cites.
  2. 2Build value dossiers that hold your biologic price under assessment

    • What a health technology assessment body looks for first in a dossier for a new originator biologic.
    • How to show the effect of biosimilar entry on your existing portfolio before the assessor raises it.
    • The real-world evidence plan that answers a price challenge years after launch.
  3. 3Pass German and French market access assessments without repeat requests

    • How to build a submission for the Federal Joint Committee's early benefit assessment in Germany.
    • What to do when the French Economic Committee for Health Products challenges your proposed price.
    • When to answer a no-added-benefit finding with new evidence and when to negotiate price.
  4. 4Set tiered prices that hold up against parallel trade

    • How to set price tiers by country so one low tier does not become the price everywhere.
    • When to offer a volume-based agreement and when an outcomes-based contract fits better.
    • The tender moves that protect your share when parallel trade undercuts your tier.
  5. 5Write contract clauses that close the most favored nation trap

    • Which rebate and price adjustment clauses belong in every European supply agreement.
    • Why a most favored nation clause in one contract can quietly cut your price in another country.
    • The wording that stops off-label use from triggering contract penalties you never priced in.
  6. 6Defend your price when a national authority re-evaluates it

    • How to slow price erosion from the day a competing biosimilar reaches the market.
    • What authorities ask for in a post-launch reimbursement re-evaluation, and in what form.
    • The data you must collect from launch day so a compliance check finds nothing missing.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

6 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h in the briefing length and 5 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 54 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team